Literature DB >> 28174174

Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women.

Patrick R Lawler1,2,3,4, Akintunde O Akinkuolie1,3, Paul M Ridker2,3, Allan D Sniderman5, Julie E Buring3,4, Robert J Glynn3,4, Daniel I Chasman3, Samia Mora6,2,3.   

Abstract

BACKGROUND: It is uncertain whether measurement of circulating total atherogenic lipoprotein particle cholesterol mass [non-HDL cholesterol (nonHDLc)] or particle concentration [apolipoprotein B (apo B) and LDL particle concentration (LDLp)] more accurately reflects risk of incident coronary heart disease (CHD). We evaluated CHD risk among women in whom these markers where discordant.
METHODS: Among 27533 initially healthy women in the Women's Health Study (NCT00000479), using residuals from linear regression models, we compared risk among women with higher or lower observed particle concentration relative to nonHDLc (highest and lowest residual quartiles, respectively) to individuals with agreement between markers (middle quartiles) using Cox proportional hazards models.
RESULTS: Although all 3 biomarkers were correlated (r ≥ 0.77), discordance occurred in up to 20.2% of women. Women with discordant high particle concentration were more likely to have metabolic syndrome (MetS) and diabetes (both P < 0.001). Over a median follow-up of 20.4 years, 1246 CHD events occurred (514725 person-years). Women with high particle concentration relative to nonHDLc had increased CHD risk: age-adjusted hazard ratio (95% CI) = 1.77 (1.56-2.00) for apo B and 1.70 (1.50-1.92) for LDLp. After adjustment for clinical risk factors including MetS, these risks attenuated to 1.22 (1.07-1.39) for apo B and 1.13 (0.99-1.29) for LDLp. Discordant low apo B or LDLp relative to nonHDLc was not associated with lower risk.
CONCLUSIONS: Discordance between atherogenic particle cholesterol mass and particle concentration occurs in a sizeable proportion of apparently healthy women and should be suspected clinically among women with cardiometabolic traits. In such women, direct measurement of lipoprotein particle concentration might better inform CHD risk assessment.
© 2016 American Association for Clinical Chemistry.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28174174      PMCID: PMC5374022          DOI: 10.1373/clinchem.2016.264515

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  26 in total

Review 1.  Risk factor thresholds: their existence under scrutiny.

Authors:  M R Law; N J Wald
Journal:  BMJ       Date:  2002-06-29

2.  Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.

Authors:  Brendan M Everett; Robert J Smith; William R Hiatt
Journal:  N Engl J Med       Date:  2015-10-07       Impact factor: 91.245

Review 3.  Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications.

Authors:  Ira Tabas; Kevin Jon Williams; Jan Borén
Journal:  Circulation       Date:  2007-10-16       Impact factor: 29.690

Review 4.  Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB.

Authors:  Allan D Sniderman; Benoit Lamarche; John H Contois; Jacqueline de Graaf
Journal:  Curr Opin Lipidol       Date:  2014-12       Impact factor: 4.776

5.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Authors:  Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood
Journal:  Eur Heart J       Date:  2011-06-28       Impact factor: 29.983

6.  Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.

Authors:  S Matthijs Boekholdt; Benoit J Arsenault; Samia Mora; Terje R Pedersen; John C LaRosa; Paul J Nestel; R John Simes; Paul Durrington; Graham A Hitman; K M A Welch; David A DeMicco; Aeilko H Zwinderman; Michael B Clearfield; John R Downs; Andrew M Tonkin; Helen M Colhoun; Antonio M Gotto; Paul M Ridker; John J P Kastelein
Journal:  JAMA       Date:  2012-03-28       Impact factor: 56.272

7.  A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Authors:  Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

Review 8.  2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult.

Authors:  Todd J Anderson; Jean Grégoire; Robert A Hegele; Patrick Couture; G B John Mancini; Ruth McPherson; Gordon A Francis; Paul Poirier; David C Lau; Steven Grover; Jacques Genest; André C Carpentier; Robert Dufour; Milan Gupta; Richard Ward; Lawrence A Leiter; Eva Lonn; Dominic S Ng; Glen J Pearson; Gillian M Yates; James A Stone; Ehud Ur
Journal:  Can J Cardiol       Date:  2013-02       Impact factor: 5.223

9.  Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events.

Authors:  Samia Mora; Julie E Buring; Paul M Ridker
Journal:  Circulation       Date:  2013-12-17       Impact factor: 29.690

10.  Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials.

Authors:  George Thanassoulis; Ken Williams; Keying Ye; Robert Brook; Patrick Couture; Patrick R Lawler; Jacqueline de Graaf; Curt D Furberg; Allan Sniderman
Journal:  J Am Heart Assoc       Date:  2014-04-14       Impact factor: 5.501

View more
  20 in total

1.  Gene-Based Elevated Triglycerides and Type 2 Diabetes Mellitus Risk in the Women's Genome Health Study.

Authors:  Shafqat Ahmad; Samia Mora; Paul M Ridker; Frank B Hu; Daniel I Chasman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-01       Impact factor: 8.311

2.  Apolipoprotein B is associated with carotid atherosclerosis progression independent of individual cholesterol measures in a 9-year prospective study of Multi-Ethnic Study of Atherosclerosis participants.

Authors:  Brian T Steffen; Weihua Guan; Alan T Remaley; James H Stein; Mathew C Tattersall; Joel Kaufman; Michael Y Tsai
Journal:  J Clin Lipidol       Date:  2017-07-12       Impact factor: 4.766

3.  Association between discordance of LDL-C and non-HDL-C and clinical outcomes in patients with stent implantation: from the FU-Registry.

Authors:  Michiyo Shiiba; Bo Zhang; Shin-Ichiro Miura; Amane Ike; Daisuke Nose; Takashi Kuwano; Satoshi Imaizumi; Makoto Sugihara; Atushi Iwata; Hiroaki Nishikawa; Akira Kawamura; Kazuyuki Shirai; Shin'ichiro Yasunaga; Keijiro Saku
Journal:  Heart Vessels       Date:  2017-08-16       Impact factor: 2.037

4.  Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women.

Authors:  Deirdre K Tobias; Patrick R Lawler; Paulo H Harada; Olga V Demler; Paul M Ridker; JoAnn E Manson; Susan Cheng; Samia Mora
Journal:  Circ Genom Precis Med       Date:  2018-04

5.  Adiposity and Genetic Factors in Relation to Triglycerides and Triglyceride-Rich Lipoproteins in the Women's Genome Health Study.

Authors:  Shafqat Ahmad; Samia Mora; Paul W Franks; Marju Orho-Melander; Paul M Ridker; Frank B Hu; Daniel I Chasman
Journal:  Clin Chem       Date:  2017-11-02       Impact factor: 8.327

Review 6.  Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?

Authors:  Michel R Langlois; Børge G Nordestgaard
Journal:  Curr Cardiol Rep       Date:  2018-08-17       Impact factor: 2.931

7.  Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.

Authors:  Nicholas A Marston; Robert P Giugliano; Giorgio E M Melloni; Jeong-Gun Park; Valerie Morrill; Michael A Blazing; Brian Ference; Evan Stein; Erik S Stroes; Eugene Braunwald; Patrick T Ellinor; Steven A Lubitz; Christian T Ruff; Marc S Sabatine
Journal:  JAMA Cardiol       Date:  2022-03-01       Impact factor: 14.676

8.  [Correlation of apolipoprotein AI, apolipoprotein B and their ratio with the severity of cerebral white matter lesions].

Authors:  Weihua Huang; Tianming Lv; Huanmin Li; Shuhua Du; Canhong Yang; Shiqi Yuan
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-07-30

9.  Small Dense Low-Density Lipoprotein Cholesterol Is the Most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study.

Authors:  Hiroaki Ikezaki; Elise Lim; L Adrienne Cupples; Ching-Ti Liu; Bela F Asztalos; Ernst J Schaefer
Journal:  J Am Heart Assoc       Date:  2021-02-15       Impact factor: 5.501

10.  Apolipoprotein B discordance with low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in relation to coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Jing Cao; Sarah O Nomura; Brian T Steffen; Weihua Guan; Alan T Remaley; Amy B Karger; Pamela Ouyang; Erin D Michos; Michael Y Tsai
Journal:  J Clin Lipidol       Date:  2019-11-29       Impact factor: 4.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.